Public



European Investment Bank (EIB)

Luxembourg, 21 December 2022

Environmental and Social Completion Sheet (ESCS)

Overview	
Project Name:	AMW (EGFF)
Project Number:	2017-0198
Country:	Germany
Project Description: AMW is a pharmaceutical company specialized in the development and manufacturing of innovative drug delivery systems, i.e. technologies aimed at the targeted delivery and controlled release of pharmaceutical compounds in order to improve their efficacy,	

manufacturing of innovative drug delivery systems, i.e. technologies aimed at the targeted delivery and controlled release of pharmaceutical compounds in order to improve their efficacy, safety and convenience. The company has a broad and diversified development pipeline, focused on providing solutions in strongly growing indications such as oncology, neurology, pain therapy and dermatology, which is expected to drive significant revenue growth in the future.

Summary of Environmental and Social Assessment at Completion

The project's R&D activities concerned the development of existing and new products and are a central part of the promoter's operations. They were embedded in the existing organisational and management structure. The project activities are not listed in any annexes of the Directive 2014/52/EU amending the EIA Directive 2011/92/EU and have been carried out in existing facilities already authorised for this use.

An additional R&D and purpose-built manufacturing facility for innovative drug delivery systems was built adjacent to the company's current facility situated in Warngau, Germany. In line with the applicable national laws, the promoter obtained all the necessary permits and authorisations from the competent authorities that are required for the construction of the facility at the time of appraisal by the Bank. The afore-mentioned permits and authorisations were issued in compliance with Directive 2014/52/EU amending the EIA Directive 2011/92/EU. The facility has subsequently been audited and authorised by the relevant German authorities for the manufacturing and release of human medicinal products.

The project has been carried out according to state-of-the-art technology and has taken into consideration environmentally friendly, low energy-and-resource consuming technologies.

The promoter maintains a robust quality management system and effective operating procedures which have been duly audited by the Competent Authorities and are in-line with ICH and GMP standards.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on the above, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.